Preparation and assessment of ocular inserts containing sulbactum for controlled drug delivery

Monika Dhaka1,2  Rupa Mazumdar1, Md Rafiul Haque3

1Noida Institute of Engineering & Technology, Greater Noida, 201306, Uttar Pradesh, India
2HIMT College of Pharmacy, Department of Pharmacognosy, Knowledge park1, Gr. Noida (U.P), India
3HIMT College of Pharmacy, Department of Pharmacognosy, Knowledge park1, Gr. Noida (U.P), India

ABSTRACT

Ocuserts or Ophthalmic inserts are sterile preparations containing drug as dispersion or as solution in the polymeric support. The sulbactum is highly used as antibacterial agent in combination with other antibiotic agent. This study aims to formulate novel sulbactum ocuserts to enhance patient compliance through providing controlled drugs release from polymeric matrix. Ocuserts were prepared by solvent-casting method using different polymers HPMC, K4M, Polyvinyl alcohol, ethyl cellulose as polymer gelatin and propylene glycol and dibutyl phthalate as plasticizer in different ratios. The prepared ocuscers were physico-chemically evaluated for their weight, thickness, drug content uniformity, surface pH, swelling index (SI) and folding endurance. The viscosity of the polymeric solution used for the formulations was determined using Brookfield viscometer. In-Vitro Drug Release study and Accelerated stability studies were also performed. The prepared ocuserts show uniform weight, thickness and drug content. Their surface pH was in the physiological range and showed acceptable folding endurance. HPMC formulas had higher SI values. Results of In-vitro testing for one of the prepared ocuserts shows slow release of drugs up to 24 hours. One of the prepared ocuserts is promising for once-daily effective and safe drug delivery system of sulbactum for glaucoma treatment.

Keyword: Ocuserts, sulbactum, viscosity, Ophthalmic

INTRODUCTION

Ophthalmic drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical researchers1. Ocuserts augments contact time, longrunning duration of action, improves bioavailability, diminishes the frequency of administration and therefore achieves good patient compliance. It is also outlook to administer the drug to inflamed eye due to sustained release of the medication from ocuserts. Furthermore, ocuserts are beneficial in saving time to the healthcare professionals. The efficacy of any ophthalmic preparation depends on the tissues for providing hoped therapeutic response2. The advantage of ocular inserts, which are solid devices placed in the cul-de-sac of the eye in comparison with liquid formulations are numerous. Because of the prolonged retention of the devices and a controlled release, the effective drug concentration in the eye can be ensured over an extended time period. Dosing of the drug is also more accurate and the risk of systemic side-effects is decreased3. Viral conjunctivitis and bacterial conjunctivitis may affect one or both eyes. Viral conjunctivitis usually produces a watery or mucous discharge. Bacterial conjunctivitis often produces a thicker, yellow - green discharge and may be associated with a respiratory infection or with a sore throat4. Sulbactam, a new 3-lactamase inhibitor, has pharmacokinetic characteristics in humans similar to those of ampicillin and amoxicillin. Sulbactam is a semisynthetic β-lactamase inhibitor which when combined with certain β-lactam antibacterials extends their activity against bacteria that are normally resistant to the antibiotic due to production of β-lactamases. In combination with ampicillin, it extends the antibacterial activity of ampicillin to include β-lactamase-producing strains which are otherwise resistant, including Bacteroides fragilis, and increases the susceptibility of many sensitive strains5. Sulbactam is poorly absorbed after oral administration and sulbactam/ampicillin is therefore administered parenterally, although another linked sulbactam-ampicillin compound, sulfamicillin, has been developed which is well absorbed after oral administration6.
The basic pharmacokinetic characteristics of sulbactam after parenteral administration are similar to those of ampicillin. Sulbactam is poorly absorbed orally. This is an alternate approach to improve the bioavailability is the use of polymeric solutions, which change to a gel as a result of exposure to the physiological temperature, pH or ionic composition of lacrimal fluid.

MATERIALS AND METHODS

Chemicals

Sulbactum, HPMC, K4M, Polivinyl Alcool and Dibutyl phthalate procured from Nellu medicare, New delhi. Gelatin, Ethyl cellulose and Propylene glycol were obtained from CDH Pvt Limited New Delhi. All solvents and reagents were of analytical grade.

Method of film preparation

The 15 formulations were prepared using various steps. The different formulation of sulbactum ocusert is given in table 1. The ocuserts were prepared by solvent casting. Sulbactum was accurately weighed and dissolved in distilled water. Pre-determined polymer was weighed and dissolved in distilled water separately in another beaker. Then clear drug solution was poured into polymer solution with constant stirring to get a homogeneous solution. Required amount of propylene glycol was added and mixed well. The resulting solution was prepared by casting method. Films are allowed to dry at room temperature for 48hr, after complete drying the films were cut with of cork borer of size 8mm so that each ocuserts will contain 1mg of the drug.

Table 1. Formulation of the sulbactam ocuserts

| Batch | DRUG (mg) | HPMCK4M (mg) | PVA (mg) | GELATIN (mg) | RATIO | Plasticizer | Rate controlling |
|-------|-----------|---------------|----------|--------------|-------|-------------|-----------------|
| SB1   | 40        | 40            | -        | -            | 1:1   | 30% w/w of the dry polymer | 4% |
| SB2   | 40        | 40            | -        | -            | 1:1   | 6% |
| SB3   | 40        | 60            | -        | -            | 1:1.5 | 4% |
| SB4   | 40        | 60            | -        | -            | 1:1.5 | 6% |
| SB5   | 40        | 80            | -        | -            | 1:2   | 4% |
| SB6   | 40        | 80            | -        | -            | 1:2   | 6% |
| SB7   | 40        | -             | 40       | -            | 1:1   | 4% |
| SB8   | 40        | -             | 40       | -            | 1:1   | 6% |
| SB9   | 40        | -             | 80       | -            | 1:2   | 4% |
| SB10  | 40        | -             | 80       | -            | 1:2   | 6% |
| SB11  | 40        | -             | -        | 40           | 1:3   | 4% |
| SB12  | 40        | -             | -        | 40           | 1:3   | 6% |
| SB13  | 40        | -             | -        | 60           | 1:1   | 4% |
| SB14  | 40        | -             | -        | 60           | 1:1   | 6% |
| SB15  | 40        | -             | -        | 80           | 1:1.5 | 4% |

Preparation of the rate controlling membrane

Ethyl cellulose was dissolved in chloroform. Required quantity of dibutyl phthalate was added and stirred until to get a clear solution. Then it was poured over a clear glass plate and allowed to dry.

Sealing

The prepared rate controlling membrane and drug reservoir were cut into circular shape by using special mould after sufficient drying. The drug–matrix films were kept and fixed in between the rate controlling membrane. The ocuserts containing sulbactum is shown in Figure 1.
Evaluation of ocular inserts

The prepared ocular inserts were evaluated for the following parameters as described below.

Physical appearance

All the formulated ocular inserts were evaluated for the physical characters such as size, shape, colour and smoothness.

Uniformity of thickness

Films were evaluated for the thickness using a vernier calliper. The average of three readings was taken at different points of films, and the mean thickness was calculated. The standard deviations (SD s) in thickness were computed from the mean value.

Weight Variation

The weight variation test was carried out using electronic balance by weighing 3 patches from each formulation. The mean value was calculated, and the standard deviations of weight variation were computed from the mean value.

Folding Endurance

The folding endurance is expressed as the no of folds (number of times the insert is folded at same place ) either to break specimen or to develop visible cracks. This test is important to check the ability of sample to withstand folding. This can also give an indication of brittleness. The specimen was folded in centre, between the fingers and thumbs and then opened. This was termed as 1 folding. This process was repeated till the insert showed breakage and cracks in centre of insert. The total folding operation was named as folding endurance value 3.

Surface pH

Insert film were allowed to swell for 30 minutes in 1 ml of distilled water. These swollen films were then removed and placed under digital pH meter to determine surface pH.

Swelling index

Initially films were weighed and placed separately in beakers containing 4 ml distilled water. At regular intervals of time (every 10 minutes) the films were removed and excess water on their surface was removed using filter paper and in weight. It was then calculated as:

Swelling Index = Final weight – Initial weight x 100
Initial weight

Estimation of percentage moisture absorbed

The percentage moisture absorption test was carried out to check physical stability or integrity of ocular films. Ocular films were weighed and placed in desiccators containing 100 ml of saturated solution of aluminium chloride. After three days the ocular films were taken out and reweighed. The percentage moisture absorption was calculated using the following equation 10.

\[ \text{Percentage moisture absorption} = \frac{\text{Final weight} - \text{Initial weight}}{\text{Initial weight}} \times 100 \]

Drug content

For drug content uniformity, the ocuserts were placed in 5 ml of p H 7.4 phosphate buffer and were crushed to extract the drug from ocuserts. The solution was filtered through a Whitman’s filter paper and filtrate was suitably diluted with buffer solution. The absorbance of the resulting solution was measured at 259 nm.

In vitro diffusion study

The drug release pattern from the ocusert was studied by using a semipermeable membrane that is chorioallantoic membrane from the egg which acts as a corneal epithelium. In vitro diffusion of the drug from different ocular inserts was studied using diffusion cell. In the donor compartment of the cell ocular insert was placed and in receptor compartment phosphate buffer (p H 7.4) is place in and receptor compartment phosphate buffer (PH 7.4) is place in order to simulate the tear volume. 0.7ml of phosphate buffer (p H 7.4) was placed and maintain at the same level throughout the study. Egg membrane (semipermeable membrane) was placed between both the compartments. The surface of the membrane was in contact in media in receptor compartment the membrane was receptor compartment is stirred continuously using a magnetic stirrer and temperature was maintained 37 ± 0.5°C. At definite time intervals, 3ml of aliquots were analyzed spectrophotometrically at λ max 259 nm 12.

Accelerated stability study

Stability of the pharmaceutical preparation can be defined as “the capability of a particular formulation in a specific system to remain within its physical, chemical, microbiological, therapeutic and toxicological specifications throughout its shelf life.” The purpose of stability testing is to provide evidence on how the quality of a substance or drug product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light, enabling recommended storage condition, re-test periods and self lives to be established. In the presence study, the formulation was selected for the study, and ocuserts were packed in amber-colored bottles tightly plugged with cotton and capped. They were exposed to various to various temperatures (37°C, 50°C, 4°C) for a period of one month. Films were evaluated for physical appearances, weight variation, thickness, drug content 12.

RESULTS

Physical appearance

The fabricated film was thin, transparent and visually smooth surface. The drug and polymer distribution is uniform.

Table 2. Characterisation of sulbactum

| Test      | Specification                  | Observations       | Remarks |
|-----------|--------------------------------|--------------------|---------|
| Description | White powder                  | White powder       | Complies|
| Solubility | It is freely soluble in water, methanol | It was soluble in water | Complies |
| Odour     | Odourless                      | Odourless          | Complies|
| Melting point | 150-200°C                  | 170                | Complies|
| LOD       | NMT 1%                         | 0.52%              | Complies|

ISSN: 2250-1177 [68] CODEN (USA): JDDTAO
Thickness uniformity

The thickness of drug loaded film was measured at three different points with the help of vernier caliper, result was given in Table 3 and the result indicate that prepared ocucets were uniform in thickness.

Uniformity of weight

Drug loaded films were tested for uniformity in weight and the results was given in Table 5.6, indicate that the uniform distribution of drug and polymer.

Folding endurance test

The recorded folding endurance test was found to be in the range of 200-300. This indicates the flexibility of the films; results were given in Table 3.

Surface pH

Surface pH of all the formulation was measured using digital pH meter values were given in Table 3. The surface pH of all the formulation was neutral so no eye irritation was expected.

| Batch | Thickness (mm) | Weight variation (mg) | Folding endurance | Surface pH |
|-------|----------------|-----------------------|-------------------|------------|
| SB1   | 0.25 ± 0.0     | 24.3 ± 0.1            | 215±2.9           | 6.99±0.0   |
| SB2   | 0.19 ± 0.0     | 23.5±0.6              | 195±7.2           | 7.32±0.1   |
| SB3   | 0.2 ± 0.1      | 25.6±0.3              | 220±5.3           | 7.65±0.2   |
| SB4   | 0.21 ± 0.3     | 25.02±0.3             | 230±2.7           | 6.76±0.1   |
| SB5   | 0.25 ± 0.1     | 21.68±0.5             | 215±2.9           | 6.89±0.2   |
| SB6   | 0.26 ± 0.2     | 24.3±0.1              | 225±3.9           | 7.12±0.1   |
| SB7   | 0.21 ± 0.2     | 22.09±0.3             | 275±2.6           | 7.01±0.2   |
| SB8   | 0.24±0.1       | 23.05±0.3             | 230±5.0           | 7.28±0.5   |
| SB9   | 0.26±0.1       | 26.03±0.2             | 258±3.5           | 6.89±0.3   |
| SB10  | 0.31±0.1       | 24.1±0.5              | 267±2.3           | 6.66±0.01  |
| SB11  | 0.24±0.1       | 25.07±0.01            | 226±4.3           | 7.3±0.2    |
| SB12  | 0.25±0.2       | 27.51±0.4             | 229±4.1           | 7.33±0.2   |
| SB13  | 0.32±0.1       | 25.08±0.2             | 222±0.3           | 7.23±0.1   |
| SB14  | 0.33±0.1       | 28.51±0.4             | 198±7.2           | 6.78±0.3   |
| SB15  | 0.33±0.2       | 28.51±0.3             | 198±7.0           | 6.78±0.32  |

Swelling index

The swelling of drug loaded films in 4 ml double distilled water was observed till 60 min. The data for increased in weight were given in Table no 4.

| Time (min) | SB1  | SB2  | SB3  | SB4  | SB5  | SB6  | SB7  | SB8  |
|------------|------|------|------|------|------|------|------|------|
| 0          | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 10         | 15.1%| 10.2%| 20.3%| 18.1%| 12.8%| 15.6%| 14.2%| 17.6%|
| 20         | 33.5%| 18.6%| 27.8%| 25.2%| 19.4%| 21.6%| 20.3%| 24.5%|
| 30         | 45.5%| 25.2%| 36.6%| 32.3%| 26.5%| 29.7%| 26.8%| 32.8%|
| 40         | 57.5%| 30.5%| 45.8%| 39.5%| 35.8%| 36%  | 32.6%| 41.5%|
| 50         | 63.5%| 45.8%| 50.0%| 46.7%| 32.2%| 37.3%| 42.5%| 47.2%|
| 60         | 70.2%| 47.8%| 56.3%| 50.3%| 52.3%| 41.3%| 51.3%| 55.6%|

| Time (min) | SB9 | SB10 | SB11 | SB12 | SB13 | SB14 | SB15 |
|------------|-----|------|------|------|------|------|------|
| 0          | 0   | 0    | 0    | 0    | 0    | 0    | 0    |
| 10         | 22.1%| 10.2%| 15.6%| 17.1%| 20.1%| 21.2%| 15.23%|
| 20         | 28.6%| 14.7%| 20.1%| 22.5%| 26.7%| 23.8%| 23.0%|
| 30         | 35.2%| 20.6%| 25.1%| 28.6%| 33.5%| 36.6%| 24.2%|
| 40         | 42.5%| 25.7%| 32.2%| 35.4%| 40.5%| 44.6%| 36.2%|
| 50         | 49.9%| 30.8%| 39.4%| 42.3%| 45.6%| 50.6%| 47.5%|
| 60         | 53.2%| 37.6%| 44.9%| 45.1%| 50.1%| 53.2%| 56.9%|
Percentage moisture absorbed
The percentage moisture absorbed was determined and the results were shown in table 5.

Percentage moisture loss
The percentage moisture loss was determined and the results were shown in table 5.

Drug Content
In order to make sure the uniform dispersion of drug in films, drug content test was carried out. Drug content was analysed by UV spectroscopy at lambda max 259 using blank sample as reference sample. The percentage drug content result was given in table 5.

Viscosity
As ratio of drug polymer and the percentage of ethyl cellulose vary, there was a slight variation in the viscosity of all the formulation was observed. Viscosity of all the formulation was in the range of 56.4 to 70.2 cp. It initialized that it had good adhesion with the conjunctiva.

Table 5. Results of moisture absorbed, moisture loss, drug content and viscosity

| Batch  | %Moisture absorbed | %Moisture loss | %Drug content | Viscosity (Cp) |
|--------|-------------------|----------------|---------------|--------------|
| SB 1   | 4.8±0.2           | 4.8±0.3        | 92.6±0.2      | 62.1         |
| SB 2   | 3.7±0.1           | 3.1±0.2        | 95.5±0.3      | 66.2         |
| SB 3   | 5.6±0.1           | 5.5±0.1        | 92.2±0.4      | 66.3         |
| SB 4   | 4.4±0.1           | 5.7±0.1        | 93.5±0.6      | 64.7         |
| SB 5   | 6.7±0.2           | 7.3±0.1        | 97.6±0.4      | 66.2         |
| SB 6   | 4.2±0.1           | 4.2±0.1        | 94.7±0.8      | 66.5         |
| SB 7   | 4.8±0.2           | 5.1±0.1        | 95.2±0.9      | 69.8         |
| SB 8   | 4.3±0.1           | 5.8±0.2        | 95.8±0.7      | 41.4         |
| SB 9   | 5.2±0.1           | 6.5±0.5        | 96.2±0.7      | 45.3         |
| SB 10  | 4.7±0.1           | 5.8±0.0        | 97.3±0.6      | 49.4         |
| SB 11  | 5.3±0.1           | 5.6±0.1        | 98.2±0.9      | 52.2         |
| SB 12  | 4.5±0.1           | 4.8±0.2        | 97.3±0.5      | 55.6         |
| SB 13  | 6.3±0.2           | 5.6±0.2        | 96.4±0.9      | 60.3         |
| SB 14  | 4.6±0.2           | 6.1±0.1        | 94.7±0.8      | 62.3         |
| SB 15  | 4.2±0.2           | 6.1±0.6        | 92.6±0.2      | 62.1         |

In-Vitro Drug Release study
The in-vitro drug release study of sulbactam osccuts was carried out using egg membrane as semipermeable membrane in phosphate buffer pH 7.4. The apparatus was designed with the objective of mimicking the conditions of ocular activity to certain extent. The release data were given in table no. 6.

Table 6. Results of In-Vitro Drug Release study of sulbactam

| Time (hrs) | Cumulative % drug release |
|------------|---------------------------|
|            | SB1 | SB2 | SB3 | SB4 | SB5 | SB6 | SB7 | SB8 |
| 0          | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| 1          | 2.17±0.90 | 6.34±0.132 | 16.8±0.43 | 15.1±0.12 | 11.8±0.35 | 13.8±0.27 | 10.3±0.33 | 14.3±0.45 |
| 2          | 6.09±0.45 | 6.3±0.131 | 27.6±0.1 | 27.3±0.7 | 19.5±0.2 | 20.7±0.4 | 19.9±0.3 | 22.3±0.1 |
| 3          | 9.23±0.89 | 27.5±0.03 | 30.6±0.3 | 31.6±0.2 | 24.7±0.4 | 29.4±0.3 | 28.4±0.5 | 27.6±0.2 |
| 4          | 10.6±0.21 | 28.5±0.7 | 34.9±0.2 | 36.2±0.23 | 28.2±0.3 | 32.4±0.6 | 30.4±0.6 | 31.4±0.6 |
| 5          | 17.1±0.08 | 29.8±0.5 | 37.4±0.6 | 41.8±0.2 | 32.4±0.5 | 34.2±0.4 | 34.1±0.4 | 35.7±0.2 |
| 6          | 20.1±0.02 | 31.9±0.6 | 41.8±0.2 | 47.7±0.4 | 34.2±0.6 | 36.5±0.9 | 38.9±0.5 | 37.9±0.6 |
| 7          | 24.5±0.02 | 39.3±0.3 | 47.6±0.2 | 49.9±0.3 | 36.0±0.6 | 40.5±0.8 | 40.6±0.6 | 44.2±0.3 |
| 8          | 28.6±0.06 | 42.0±0.4 | 50.6±0.3 | 54.2±0.4 | 39.2±0.3 | 44.6±0.4 | 42.9±0.6 | 50.4±0.3 |
| 9          | 30.4±0.01 | 46.5±0.2 | 55.0±0.4 | 57.0±0.4 | 43.8±0.6 | 47.6±0.5 | 43.4±0.4 | 53.7±0.3 |

| Time (hrs) | Cumulative % drug release |
|------------|---------------------------|
|            | SB9 | SB10 | SB11 | SB12 | SB13 | SB14 | SB15 |
| 0          | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| 1          | 11.8±0.09 | 9.0±0.3 | 16.6±0.3 | 22.3±0.9 | 24.7±0.3 | 10.5±0.9 | 22.7±0.3 |
| 2          | 15.2±0.4 | 15.4±0.4 | 24.1±0.1 | 32.5±0.7 | 32.4±0.6 | 16.4±0.4 | 26.5±0.2 |
| 3          | 26.6±0.3 | 19.6±0.6 | 31.3±0.7 | 37.2±0.4 | 46.1±0.2 | 23.4±0.5 | 29.6±0.3 |
| 4          | 30.5±0.2 | 28.4±0.5 | 35.0±0.1 | 44.5±0.9 | 49.8±0.3 | 26.4±0.6 | 30.4±0.6 |
| 5          | 34.6±0.5 | 32.2±0.1 | 42.5±0.9 | 51.1±0.2 | 54.4±0.8 | 33.9±0.3 | 35.0±0.3 |
| 6          | 40.4±0.4 | 35.6±0.6 | 48.6±0.8 | 55.4±0.6 | 57.4±0.3 | 38.3±0.5 | 45.1±0.3 |
| 7          | 45.3±0.3 | 41.3±0.7 | 52.4±0.6 | 62.8±0.3 | 60.9±0.4 | 40.1±0.6 | 46.4±0.7 |
| 8          | 47.5±0.6 | 45.6±0.8 | 54.9±0.4 | 68.4±0.6 | 70.4±0.6 | 44.8±0.9 | 49.9±0.4 |
| 9          | 48.5±0.3 | 51.8±0.5 | 59.5±0.6 | 73.4±0.6 | 74.6±0.6 | 47.5±0.3 | 52.3±0.5 |
Accelerated stability studies

The optimized formulation was subjected to short term stability testing. Films wrapped in aluminium foil and kept in a humidity chamber maintain at 37°C and 50°C and 4°C of period of 1 month at different temperature as per ICH guidelines. Results on stability study were given in table 7. From the above results there are a slight change occurs at a temperature of 50°C and there is no significant change was observed at other temperature.

| Temperature(°C) | Physical appearance | Evaluation Parameters |
|----------------|---------------------|-----------------------|
|                |                     | Weight variation(mg)  | Thickness(mm) | Drug content(mg) |
| 37             | No change           | 25.2                  | 0.2           | 1.0             |
| 50             | No change           | 25.1                  | 0.2           | 0.9             |
| 4              | No change           | 25.2                  | 0.2           | 1.0             |

DISCUSSION

Sulbactum drug is used against many diseases[7]. It is indicated for eye diseases. In the present study an attempt was made to develop various batches of sulbactum ocuserts using solvent casting method and they were evaluated. Polymers such as HPMC, K4M, PVA, Ethyl cellulose and gelatin were good film forming polymer. The percentage of ethyl cellulose provided a sustained release of the drug from polymeric reservoir. The results of the drug compatibility studies revealed that there was no chemical interaction between the pure drug and the excipients used. In evaluation parameters, the viscosity of all formulation was found to be in between 50 to 723 cp. It is indicate that it has good adhesive with the conjunctiva. The thickness of all the films was to be in the range of 0.180 to 0.323 mm which shows that it is easily inserted in to the eye and does not produce any irritation in eye, weight of all the films were found to be in between 20.01 to 28.02 mg which that there is uniform distribution of the drug and polymer, folding endurance of the formulation were to be in the range of 200-300 and the surface pH of all the formulation was found to be in range 6.60-7.5, compatible with the tear fluid pH that is 7.4, which shows that the preparations are sterile and safe to be used in the eye. All these results showed that ocuserts prepared compatible with the eye and does not produce any inflammation or redness in the eye. In-vitro drug release from SB ocuserts in phosphate buffer pH 7.4. The optimized SB 10 showed 97% drug release.

CONCLUSIONS

From the experimental findings it had been concluded that the said promising batch SB10 would be able to benefits such as increase residence time, prolong drug release, reduction in the frequency of administration and thereby may help to improve the patient compliance with the limitation that the formulation is non-erodible. The drug remained intact and stable in the ocuserts as well as in the storage with no apparent chemical interaction between the drug and excipients in future further work will be progress to establish the therapeutic utility of these systems by pharmacokinetic and pharmacodynamics studies in humans.

ACKNOWLEDGEMENT

Authors are thankful to Department of Pharmaceutics, NIET College of Pharmacy for providing all necessary facilities for this work.

CONFLICT OF INTEREST: None declared.

SOURCE OF SUPPORT: Nil

REFERENCES

1. Pandit JK, Bharathi D, Srinatha A, Ridhurkar DN and Singh S. Long acting ophthalmic formulation of indomethacin: Evaluation of alginate gel systems. Indian J Pharm Sci 2007; 69(1):37-40.
2. Sridivya B, Cardoza RM and Amin PD. Sustained ophthalmic delivery of ofloxacin from pH triggered in situ gelling system. J Controlled Release. 2001; 73(2-3):205-11.
3. Bharath S. Sustained ophthalmic delivery of ofloxacin from an ionactivated in situ gelling system. Pak J Pharm 2009; 22(2):175-9.
4. Weisan P, ZhidongL, Jiawei L, Shufang N, Hui L and Pingtian D. Study of alginate/HPMC based in situ gelling ophthalmic delivery system for atifloxacin. Int J Pharm; 2006; 315:12-17.
5. Shapiro AB, Gao N, Jahic H, Carter NM, Chen A, Miller AA. Reversibility of covalent, broad-spectrum serine -lactamase inhibition by the diazabicyclooctenone ETX2514. ACS Infect Dis, 2017; 3:833– 844.
6. Adnan S, Paterson DL, Lipman J, Roberts JA. Ampicillin/sulbactam: its potential use in treating infections in critically ill patients. Int J Antimicrob Agents, 2013; 42(5):384–9.
7. Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015; 59(3):1680–9.
8. Noguchi JK, Gill MA. Sulbactam: a beta-lactamase inhibitor. Clin Pharm, 1988; 7(1):37–51.
9. Maria Gerald Rajan NS, Jayaprakash S, Somnath S. Design And Evaluation Of Polymeric Ocular Drug Delivery System For Controlled Release Of Tetracycline HCl. Ind J Pharm Sci, 2017; 63(6):526-528.
10. Di Cola G; Burgalassi S; Chetoni P; Fiaschi MP; Zambito Y, Saettone MF. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Int J Pharm 2001; 215:101-111.
11. Sridivya B; Rita M; Cardoza, PD Amin. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Rel 2001; 73:205-211.
12. Lang JC. Ocular drug delivery conventional oocular formulations. Adv Drug Deliv Rev. 1995; 16:39-43.